High Risk Coronary Artery Disease
2
0
0
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Azd5718 Ir Tablet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 2 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD)
A Study to Estimate the Effect of AZD5718 on the Pharmacokinetics (What Does the Body Does to the Drug) of Rosuvastatin to Measure the Relative Bioavailability (the Extent to Which a Drug or Other Substance Becomes Available to the Body) of AZD5718 Oral Suspension vs AZD5718 Immediate Release Tablet
Research Network
Common Treatments
- Azd5718 Ir Tablet1
- Azd5718 Oral Suspension1
- Rosuvastatin1
- Evolocumab1
Active Sponsors
- AstraZeneca1
- Beijing Anzhen Hospital1
Top Investigators
Beijing Anzhen Hospital
PAREXEL Early Phase Clinical Unit London
Related Conditions
- Dyslipidemia1